S128: A RANDOMISED COMPARISON OF CPX-351 AND FLAG-IDA IN HIGH RISK ACUTE MYELOID LEUKAEMIA. RESULTS FROM THE NCRI AML19 TRIAL

• N. Russell,
• C. Wilhelm-Benartzi,
• S. Knapper,
• L. Batten,
• J Canham,
• E. Hinson,
• U. Malthe Overgaard,
• J. Othman,
• R. Dillon,
• P. Mehta,
• P. Kottaridis,
• J. Cavenagh,
• C. Hemmaway,
• C. Arnold,
• M. Dennis

Affiliations

N. Russell

1 Guy’s and St Thomas’ NHS Foundation Trust, Department of Haematology, London

C. Wilhelm-Benartzi

2 Centre for Trials Research

S. Knapper

3 School of Medicine, Cardiff University, Cardiff, United Kingdom

L. Batten

2 Centre for Trials Research

J Canham

2 Centre for Trials Research

E. Hinson

2 Centre for Trials Research

U. Malthe Overgaard

4 Copenhagen University Hospital, Copenhagen, Denmark

J. Othman

5 Department of Medical and Molecular Genetics, Kings College London, London

R. Dillon

5 Department of Medical and Molecular Genetics, Kings College London, London

P. Mehta

6 University Hospitals of Bristol and Weston NHS Trust, Bristol

P. Kottaridis

7 University College London Hospitals NHS Foundation Trust

J. Cavenagh

8 Department of Haematology, St Bartholomew’s Hospital, London, United Kingdom

C. Hemmaway

9 Aukland Hospital, Aukland, New Zealand

C. Arnold

10 Belfast City Hospital, Belfast

M. Dennis

11 The Christie NHS Foundation Trust. On behalf of the NCRI AML Working Group, Manchester, United Kingdom